ATE447959T1 - Methode zur reduktion des schmerzempfindens - Google Patents

Methode zur reduktion des schmerzempfindens

Info

Publication number
ATE447959T1
ATE447959T1 AT01982091T AT01982091T ATE447959T1 AT E447959 T1 ATE447959 T1 AT E447959T1 AT 01982091 T AT01982091 T AT 01982091T AT 01982091 T AT01982091 T AT 01982091T AT E447959 T1 ATE447959 T1 AT E447959T1
Authority
AT
Austria
Prior art keywords
pain
sensation
reducing
anolgs
saxitoxin
Prior art date
Application number
AT01982091T
Other languages
English (en)
Inventor
Qingbin Dong
Frank Haykong Shum
Original Assignee
Wex Medical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wex Medical Ltd filed Critical Wex Medical Ltd
Application granted granted Critical
Publication of ATE447959T1 publication Critical patent/ATE447959T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Electrotherapy Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Laser Surgery Devices (AREA)
AT01982091T 2000-09-18 2001-09-11 Methode zur reduktion des schmerzempfindens ATE447959T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNB001245171A CN1284536C (zh) 2000-09-18 2000-09-18 河豚毒素或蛤蚌毒素及其类似物在制备用于全身镇痛的镇痛药中的应用
PCT/CN2001/001391 WO2002022129A1 (en) 2000-09-18 2001-09-11 A method of analgesia

Publications (1)

Publication Number Publication Date
ATE447959T1 true ATE447959T1 (de) 2009-11-15

Family

ID=4590472

Family Applications (2)

Application Number Title Priority Date Filing Date
AT04022073T ATE542534T1 (de) 2000-09-18 2001-09-11 Methode zur schmerzbekämpfung
AT01982091T ATE447959T1 (de) 2000-09-18 2001-09-11 Methode zur reduktion des schmerzempfindens

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT04022073T ATE542534T1 (de) 2000-09-18 2001-09-11 Methode zur schmerzbekämpfung

Country Status (26)

Country Link
US (1) US6407088B1 (de)
EP (3) EP2298306B1 (de)
JP (1) JP2004508404A (de)
KR (2) KR100891568B1 (de)
CN (1) CN1284536C (de)
AT (2) ATE542534T1 (de)
AU (1) AU2002213785A1 (de)
BG (1) BG107690A (de)
BR (1) BR0113961A (de)
CA (1) CA2421562C (de)
DE (1) DE60140466D1 (de)
EA (1) EA004870B1 (de)
EE (1) EE200300106A (de)
ES (1) ES2435463T3 (de)
HR (1) HRP20030202A2 (de)
HU (1) HUP0302677A3 (de)
IL (1) IL154342A0 (de)
IS (1) IS6719A (de)
MX (1) MXPA03002389A (de)
NO (1) NO323960B1 (de)
PL (1) PL360616A1 (de)
SK (1) SK3732003A3 (de)
UA (1) UA76960C2 (de)
WO (1) WO2002022129A1 (de)
YU (1) YU17103A (de)
ZA (1) ZA200301852B (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE289295T1 (de) 1997-04-22 2005-03-15 Euro Celtique Sa Die verwendung von durch carbozyklische und heterozyklische reste substituierte semicarbazonen und thiosemicarbazonen als natriumkanalblocker
CN1236773C (zh) 2000-11-22 2006-01-18 南宁枫叶药业有限公司 用于镇痛、麻醉或治疗药物依赖性的制剂
US7119062B1 (en) 2001-02-23 2006-10-10 Neucoll, Inc. Methods and compositions for improved articular surgery using collagen
CN1269482C (zh) * 2001-05-18 2006-08-16 威克斯医药有限公司 钠离子通道阻断剂和阿片类镇痛剂在制备用于对哺乳动物进行协同镇痛的药物中的应用
CN1203860C (zh) * 2001-06-22 2005-06-01 威克斯医药有限公司 钠离子通道阻断剂和阿司匹林在制备用于对哺乳动物进行协同镇痛的药物中的应用
MXPA04004543A (es) 2001-11-15 2005-03-31 Micro Algae Corp Composiciones farmaceuticas que contienen 3,4-propinoperhidropurinas y sus usos para el bloqueo de la transmision neuronal.
AU2003250128A1 (en) * 2002-08-01 2004-02-23 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 37 (gpr37)
AU2004207010A1 (en) * 2003-01-30 2004-08-12 Dynogen Pharmaceuticals, Inc. Methods of treating lower urinary tract disorders using sodium channel modulators
CN1568999A (zh) 2003-07-14 2005-01-26 南宁枫叶药业有限公司 稳定的医药用河豚毒素冷冻干燥制剂
JP2005154368A (ja) * 2003-11-27 2005-06-16 Teikoku Seiyaku Co Ltd ジソピラミド含有神経因性疼痛の鎮痛剤
EP1796676B1 (de) * 2004-05-07 2016-03-09 Phytotox Limited Transdermale verabreichung von phycotoxinen
BRPI0510759A (pt) * 2004-05-07 2007-11-20 Phytotox Ltd método de facilitar a cura de um ferimento
US20050282836A1 (en) * 2004-06-22 2005-12-22 Weiyang Lin Solid orally ingestible formulations of tetrodotoxin
US20060034823A1 (en) * 2004-08-13 2006-02-16 Paul Reid Method of production and use of crotoxin as an analgesic
CN100363006C (zh) * 2004-08-20 2008-01-23 厦门朝阳生物工程有限公司 一种戒毒制剂及其制备方法
AU2005287511A1 (en) * 2004-09-21 2006-03-30 Wex Medical Limited Tetrodotoxin and its derivatives for the treatment of central-nervously derived neuropathic pain
KR20070092698A (ko) * 2004-09-22 2007-09-13 라보라토리오스 델 드라. 에스테브.에스.에이. 말초 신경적으로 유발된 신경병증성 통증을 치료하기 위한테트로도톡신 및 그것의 유도체
EP1714655A1 (de) * 2005-04-22 2006-10-25 Laboratorios Del Dr. Esteve, S.A. Verwendung eines Natriumkanalblockers und deren Analoga zur Behandlung von Nikotinabhängigkeit
WO2006084765A1 (en) * 2005-02-11 2006-08-17 Wex Pharmaceuticals, Inc. Use of sodium channel blockers and their analogues for the treatment of nicotine dependency
EP1690541A1 (de) * 2005-02-11 2006-08-16 Laboratorios Del Dr. Esteve, S.A. Verwendung eines Natriumkanalblockers und deren Analoga zur Behandlung von Nikotinabhängigkeit
EP1702627A1 (de) * 2005-03-18 2006-09-20 Laboratorios Del Dr. Esteve, S.A. Analgetische Kombination aus Natriumkanalblocker und Opioid Antagonisten
CA2619668A1 (en) * 2005-08-25 2007-03-01 Edge Renfeng Wang Use of sodium channel blockers for the management of musculoskeletal pain
US20100144767A1 (en) * 2005-08-25 2010-06-10 Wex Pharmaceuticals, Inc. Use of sodium channel blockers for the treatment of visceral pain or pain caused by cancer treatment
US20070148159A1 (en) * 2005-12-22 2007-06-28 Reid Paul F Use of crotoxin as an analgesic - CIP
GB0603008D0 (en) * 2006-02-14 2006-03-29 Portela & Ca Sa Method
EP1844781A1 (de) 2006-02-22 2007-10-17 Wex Pharmaceuticals Inc. Verwendung von Natriumkanalblockern für die Behandlung von vorzeitigen Wehen
WO2007110220A1 (en) * 2006-03-27 2007-10-04 Wex Pharmaceuticals Inc. USE OF 4,9-ANHYDRO-TETRODOTOXIN FOR THE TREATMENT OF DISEASES RELATED TO THE VOLTAGE-GATED SODIUM CHANNEL α SUBUNIT NAV 1.6
EP1844782A1 (de) * 2006-03-27 2007-10-17 Wex Pharmaceuticals, Inc 4,9-Anhydro-Tetrodoxin zur Behandlung von Krankheiten die in Zusammenhang mit der Potential-abhängigen Natrium-Kanal Subeinheit Nav1.6 stehen
EP1844783A1 (de) * 2006-03-27 2007-10-17 Wex Pharmaceuticals, Inc 4,9-Anhydro-Tetrodoxin zur Behandlung von Krankheiten die in Zusammenhang mit der Potential-abhängigen Natrium-Kanal Subeinheit Nav1.6 stehen
WO2007110221A1 (en) * 2006-03-27 2007-10-04 Wex Pharmaceuticals Inc. Use of sodium channel blockers for the treatment of neuropathic pain developing as a consequence of chemotherapy
CN100438873C (zh) * 2006-06-26 2008-12-03 黄致强 将河鲀毒素作为镇痛药的耐受抑制剂在制备复方镇痛制剂中的应用
EP1882692A1 (de) * 2006-07-28 2008-01-30 Wex Pharmaceuticals Inc. Dimethano-[1,3]dioxocino[6,5-D]Pyrimidine-Spiro-Derivate von Tetrodotoxin, Verfahren ihrer Herstellung und ihre Verwendung zur Behandlung von Schmerzen
EP2173167A4 (de) * 2007-07-06 2010-07-28 Nuon Therapeutics Inc Behandlung neuropathischer schmerzen
CN101352422B (zh) * 2008-09-17 2011-04-20 厦门朝阳生物工程有限公司 河豚毒素冻干粉针制剂及其制备方法
US8952152B2 (en) 2009-03-24 2015-02-10 Proteus S.A. Methods for purifying phycotoxins, pharmaceutical compositions containing purified phycotoxins, and methods of use thereof
US20120034296A1 (en) * 2009-04-08 2012-02-09 Massachusetts Institute Of Technology Prolonged duration local anesthesia with minimal toxicity
JP6112867B2 (ja) * 2010-02-10 2017-04-12 ファイトトックス リミテッドＰｈｙｔｏｔｏｘ Ｌｉｍｉｔｅｄ サキシトキシン誘導体での触覚の喪失の処置
US20120310140A1 (en) 2010-12-01 2012-12-06 Spinal Modulation, Inc. Directed delivery of agents to neural anatomy
AU2014240392A1 (en) 2013-03-14 2015-11-05 Regeneron Pharmaceuticals, Inc. Human antibodies to Nav1.7
KR102787826B1 (ko) 2013-03-15 2025-03-31 더 칠드런스 메디칼 센터 코포레이션 지속성 국소 마취용 네오삭시톡신 조합 제형
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
CN107198689A (zh) * 2017-07-11 2017-09-26 东新皓特（北京）生化科技有限公司 用于治疗疼痛病症的河豚毒素药物组合物及外用药
EP4326282A4 (de) 2021-04-23 2025-02-26 Wex Pharmaceuticals Inc. Tetrodotoxin-flüssigformulierungen
MX2024001877A (es) 2021-08-10 2024-02-28 Kymab Ltd Tratamiento de dermatitis atopica.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4022899A (en) 1973-06-12 1977-05-10 Astra Pharmaceutical Products, Inc. Synergistic local anesthetic compositions
US4029793A (en) 1973-06-12 1977-06-14 Astra Pharmaceutical Products, Inc. Synergistic local anesthetic compositions
AU1888195A (en) * 1994-03-17 1995-10-03 Nanning Maple Leaf Pharmaceutical Co. Ltd. The use of amino hydrogenated quinazoline compounds and derivatives thereof for abstaining from drug dependence
CN1072486C (zh) * 1996-09-24 2001-10-10 王维国 用于戒毒、镇痛的药剂及其制法
US6030974A (en) * 1997-04-02 2000-02-29 The Regents Of The University Of California Method of anesthesia
AU7389098A (en) * 1997-05-16 1998-12-08 Brigham And Women's Hospital Local anesthetic formulations
CN1236773C (zh) * 2000-11-22 2006-01-18 南宁枫叶药业有限公司 用于镇痛、麻醉或治疗药物依赖性的制剂
CN1269482C (zh) * 2001-05-18 2006-08-16 威克斯医药有限公司 钠离子通道阻断剂和阿片类镇痛剂在制备用于对哺乳动物进行协同镇痛的药物中的应用

Also Published As

Publication number Publication date
CA2421562C (en) 2011-05-24
ATE542534T1 (de) 2012-02-15
US6407088B1 (en) 2002-06-18
HUP0302677A2 (hu) 2003-11-28
HRP20030202A2 (en) 2005-02-28
BR0113961A (pt) 2004-01-13
EP1320369B1 (de) 2009-11-11
ZA200301852B (en) 2004-06-21
JP2004508404A (ja) 2004-03-18
CN1284536C (zh) 2006-11-15
PL360616A1 (en) 2004-09-20
DE60140466D1 (de) 2009-12-24
EA004870B1 (ru) 2004-08-26
EP2298306B1 (de) 2013-09-11
EA200300172A1 (ru) 2003-12-25
EE200300106A (et) 2005-04-15
NO20030915L (no) 2003-04-25
YU17103A (sh) 2006-03-03
NO20030915D0 (no) 2003-02-27
IS6719A (is) 2003-02-14
AU2002213785A1 (en) 2002-03-26
KR20070112864A (ko) 2007-11-27
BG107690A (bg) 2004-01-30
HUP0302677A3 (en) 2005-01-28
WO2002022129A1 (en) 2002-03-21
IL154342A0 (en) 2003-09-17
MXPA03002389A (es) 2004-03-12
CA2421562A1 (en) 2002-03-21
EP1320369A1 (de) 2003-06-25
NO323960B1 (no) 2007-07-23
ES2435463T3 (es) 2013-12-19
UA76960C2 (en) 2006-10-16
EP1563839A1 (de) 2005-08-17
EP1320369A4 (de) 2003-07-02
SK3732003A3 (sk) 2005-05-05
EP2298306A1 (de) 2011-03-23
KR20030034181A (ko) 2003-05-01
EP1563839B1 (de) 2012-01-25
KR100891568B1 (ko) 2009-04-03
CN1356104A (zh) 2002-07-03

Similar Documents

Publication Publication Date Title
DE60140466D1 (de) Methode zur reduktion des schmerzempfindens
WO2005013914A8 (en) Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain
IL181700A0 (en) Quinazoline derivatives and pharmaceutical compositions containing the same
WO2002042462A3 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
WO2004032909A3 (en) Stabilized pharmaceutical composition containing basic excipients
TW200510375A (en) New compounds
PL372809A1 (en) Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof
EP1708685A4 (de) Brauseformen von opiaten zur oralen anwendung und verfahren zur verabreichung von opiaten
WO2002088100A3 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
CY1109361T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες
WO2004087700A8 (fr) Derives du benzenesulfonamide, leur procede de preparation et leur utilisation de la douleur
BR0213449A (pt) Comprimido mastigável contendo lisina
EP1262197A3 (de) Kombinationstherapie zur Behandlung von Schlafstörungen, Schlaflosigkeit inbegriffen
WO2001008671A3 (en) Method and composition for prophylaxis and treatment of symptoms associated with cold and influenza-like illnesses
EP1387685A4 (de) Analgetische zusammensetzung und verfahren
WO2002005801A3 (en) Compositions containing diacyltartaric salts of (e)-metanicotine
WO2001060343A3 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und/oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
NZ523606A (en) Pharmaceutical compositions and methods for use
SE0000303D0 (sv) Novel compounds
BR0206087A (pt) Formulação de enxaguamento redutora para uso com ozÈnio no tratamento de cáries dentárias
WO2002076400A3 (en) Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease
TWI256388B (en) Pharmaceutical combination
BR0313305A (pt) Agente analgésico para indivìduos recém-nascidos ou fetais
MY131159A (en) New pharmaceutical compositions containing epinastine and pseudoephedrine
WO2002009668A3 (en) Pulmonary administration of flint

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties